Docs rate top specialty reps in survey

Share this article:

Physicians were asked to rank the companies that have the best general sales reps, specialty sales reps, and medical science liaisons as part of “Specialty Reps 2007: An Influential Force,” a recent Verispan survey of 4,000 physicians from across 24 different specialties.

Here's a look at what docs from each specialty had to say about the specialty sales reps that serve them.

Cardiologists rated Pfizer, Merck and Novartis first, second and third respectively as the companies with the best specialty sales forces. Gastroenterologists rated AstraZeneca, TAP and Abbott as the top three sales forces for specialty reps. Neurologists/neurosurgeons ranked Pfizer, GlaxoSmithKline, UCB and Novartis as having the best specialty reps. OB/GYNs ranked Wyeth, Ortho-McNeil and Bayer first, second and third, respectively in terms of best specialty reps. Oncologists rated Genentech, Amgen and Novartis as having the best specialty reps.

Ophthalmologists ranked Alcon, Allergan and Pfizer as the leasing sales forces in terms of specialty reps.

Pediatricians ranked Merck, GlaxoSmithKline and Shire as the top three sales forces for specialty reps. Psychiatrists ranked Eli Lilly, Janssen and Pfizer as having the leading specialty sales reps. Urologists rated Pfizer, Sanofi-Aventis and GlaxoSmithKline first, second and third, in terms of best specialty representatives.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.